Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Tamoxifen in Patients With Oesophageal Cancer
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 20
- Registration Number
- NCT02513849
- Locations
- 🇬🇧
Graduate Entry Medical School, University of Nottingham, Derby, Derbyshire, United Kingdom
🇬🇧Royal Derby Hospital, Derby, United Kingdom
Decision Aids for Tamoxifen Treatment in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 360
- Registration Number
- NCT02488603
A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Buddhist Tzu Chi General Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT02482740
- Locations
- 🇨🇳
Dept. of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, No 123, Dapi Rd, Niaosong Dist, Taiwan
🇨🇳China Medical University Hospital, Taichung, No.2, Yude Rd., North Dist.,, Taiwan
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, No.100, Ziyou 1st Rd., Sanmin Dist., Taiwan
Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs
- Conditions
- Interventions
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 600
- Registration Number
- NCT02479256
- Locations
- 🇪🇬
Ain Shams University Maternity Hospital, Cairo, Egypt
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT02476786
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Breast Cancer, Sexuality and Black Cohosh
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2017-03-20
- Target Recruit Count
- 60
- Registration Number
- NCT02467686
- Locations
- 🇧🇷
Carolina Furtado Macruz, Sao Paulo, Brazil
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- University Hospital, Essen
- Target Recruit Count
- 48
- Registration Number
- NCT02404844
- Locations
- 🇩🇪
iOMEDICO AG, Freiburg, Baden-Württemberg, Germany
Reversing Therapy Resistance With Epigenetic-Immune Modification
- Conditions
- Interventions
- First Posted Date
- 2015-03-23
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 38
- Registration Number
- NCT02395627
- Locations
- 🇺🇸
University of California, San Francisco Medical Center, San Francisco, California, United States
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 70
- Registration Number
- NCT02384239
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 104
- Registration Number
- NCT02344940
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.